scholarly journals Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer

Oncogene ◽  
2016 ◽  
Vol 36 (16) ◽  
pp. 2286-2296 ◽  
Author(s):  
A Harrod ◽  
J Fulton ◽  
V T M Nguyen ◽  
M Periyasamy ◽  
L Ramos-Garcia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Therapeutic Approaches ◽  
New Therapeutic Approaches

scholarly journals Successful Treatment of Mycobacterium chelonae Keratitis Within a Corneal Transplant Using Intrastromal Amikacin Injections—A Case Report Demonstrating the Fundamental Principles and Challenges of Infective Keratitis Management and Novel Therapeutic Approaches

2019 ◽  
Vol 6 (8) ◽  
Author(s):  
Nancy Louisa Merridew ◽  
Ravinder Singh Phagura ◽  
Edward Anderson ◽  
Louise Anne Cooley ◽  
Graeme Alfred Pollock ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Transplant Recipient ◽  
Effective Treatment ◽  
Metastatic Breast ◽  
Corneal Transplant ◽  
Therapeutic Approaches ◽  
Mycobacterium Chelonae ◽  
Novel Therapeutic

Abstract Mycobacterium chelonae keratitis is rare and difficult to treat. This is the first known case worldwide of effective treatment using intrastromal amikacin injections in a corneal transplant recipient who had metastatic breast cancer. The challenges and principles of management, applicable to other causes of infective keratitis, are reviewed.

The Future Role of PET Imaging in Metastatic Breast Cancer

2021 ◽  
Author(s):  
Kim M. Pabst ◽  
Thomas Decker ◽  
David Kersting ◽  
Timo Bartel ◽  
Miriam Sraieb ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Estrogen Receptor Status ◽  
Metastatic Breast ◽  
Ct Imaging ◽  
Whole Body ◽  
Therapeutic Approaches ◽  
Treatment Optimization ◽  
Pet Ct ◽  
Fdg Pet Ct

Background: A variety of therapeutic approaches are employed to treat patients suffering from breast cancer. Likewise, a broad spectrum of imaging ligands has been introduced for non-invasive PET/CT imaging to enable comprehensive tumor characterization and more accurate response evaluation. Summary: In recent years, novel radioactively labelled ligands have been developed for PET/CT imaging in metastatic breast cancer. One promising tracer is [18F]fluoroestradiol, which was recently approved by the Food and Drug Administration. It can be used for a whole-body assessment of estrogen receptor status. Another radionuclide currently under development is [68Ga]Ga-FAPI. In addition to new radionuclides, the field of application for existing tracers like [18F]fluorodeoxyglucose (FDG) were broadened. It has been shown that an early therapeutic response to various therapies can be detected by [18F]FDG PET/CT, which leads to early treatment optimization. Key Message: In this review, we highlighted new tracers and applications of PET/CT imaging as well as therapeutic approaches in patients with advanced breast cancer. Furthermore, we give an outlook on the application of artificial intelligence, immunoPET and liquid biopsy.

scholarly journals Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer

2020 ◽  
pp. 4-21
Author(s):  
A S Kolbin ◽  
I A Vilyum ◽  
M A Proskurin ◽  
Yu E Balikina ◽  
A V Pavlysh
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Metastatic Breast Cancer ◽  
Economic Evaluation ◽  
Triple Negative ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Target Population ◽  
Therapeutic Approaches ◽  
The Cost

Objective. To determine the pharmacoeconomical feasibility of using a combination of atezolizumab + nab-paclitaxel in the 1st line of therapy for locally advanced or metastatic triple negative breast cancer (TNBC) in adult PDL1 positive patients in the Russian healthcare system. Materials and methods. A decision analysis model was used followed by Markov modelling for the economic evaluation of the drugs in the treatment of metastatic TNBC. We used the «cost-effectiveness» analysis and the «impact on the budget» (BIA) analysis. Two therapeutic approaches were evaluated: the use of combined therapy with atezolizumab + nab-paclitaxel and monotherapy with nab-paclitaxel. The analysis included direct costs. Additionally, the obtained pharmacoeconomical indicators of the use of a combination of atezolizumab and nab-paclitaxel and other drugs for the treatment of locally advanced and metastatic breast cancer were compared. Results. The use of the estimated therapeutic approaches in the treatment of metastatic TNBC was characterized by the following costs: with a modelling horizon of 1 year, the cost of using atezolizumab in combination with nab-paclitaxel was 5,076,321 rubles per patient. The costs for the use of single agent nab-paclitaxel with was 60 % less than: — 2 020 038,78 RUB. At the same time, the effectiveness of therapy with a combination of atezolizumab and nab-paclitaxel clinically significantly exceeded that of nab-paclitaxel monotherapy: a 38 % reduction in the risk of death or progression, a 10-fold increase in the frequency of complete response to therapy (10 vs 1 %), and a 7-month increase in the median overall survival (25 vs 18 months). The economic evaluation of the combination of atezolizumab with nab-paclitaxel was carried out with the calculation of the incremental cost-effectiveness ratios (ICER) — the calculation of the additional cost for each additional year of life in comparison with standard therapy. Due to the fact that currently in Russia for patients with metastatic TNBC no similar performance modes of therapy ICER for the combination atezolizumab + nab-paclitaxel compared with the ICER for palbociclib in combination with fulvestrant (drugs, showed improved overall survival in clinical research and included in clinical guidelines for the treatment of diseases of the same class ICD-10 in locally advanced and metastatic breast cancer). The ICER for overall survival at the end of the first year of follow-up for atezolizumab + nab-paclitaxel and palbociclib + fulvestrant was 30.5 million rubles and 47.4 million rubles, respectively. For the combination of atezolizumab + nab-paclitaxel, ICER is lower than the similar ICER for the palbociclib + fulvestrant mode by 36 %. Analysis of trends in the weighted average cost of systemic pathogenetic treatment of breast cancer (breast cancer) shows the following: increased use of the combination of atezolizumab + nab-paclitaxel for the treatment of patients with metastatic TNBC doesn’t lead to a considerable growth in the cost of therapy in patients with breast cancer — providing therapy to 1400 patients that includes the entire target population of patients with TNBC and expression of PD-L1 in Russia changes in the costs of chemotherapy and immunotherapy of breast cancer will remain within 2.6 %. Conclusion. Pharmacoeconomic indicators of the use of atezolizumab in combination with nab-paclitaxel are more cost-effective in comparison with other expensive schemes for the treatment of breast cancer, and tumors of other localities that are actively used in current practice, which suggests the acceptability and feasibility of introducing and expanding the use of this therapeutic option in the target population.

scholarly journals Genomic Alteration in Metastatic Breast Cancer and Its Treatment

2020 ◽  
pp. 30-43
Author(s):  
Allen Li ◽  
Stephen M. Schleicher ◽  
Fabrice Andre ◽  
Zahi I. Mitri
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Mutation Detection ◽  
Pik3ca Mutation ◽  
Metastatic Breast ◽  
Detection Methods ◽  
Genomic Alteration ◽  
Therapeutic Approaches ◽  
Genomic Alterations

Metastatic breast cancer (mBC) remains responsible for the majority of breast cancer deaths. Whereas clinical outcomes have improved with the development of novel therapies, resistance almost inevitably develops, indicating the need for novel therapeutic approaches for the treatment of mBC. Recent investigations into mBC genomic alterations have revealed novel and potential therapeutic targets. Most notably, therapies against PIK3CA mutation and germline BRCA1/2 mutations have solidified the role of targeted therapy in mBC, with treatments against these alterations now approved by the U.S. Food and Drug Administration (FDA) on the basis of clinical benefit for patients with mBC. Familiarity with relevant genomic alterations in mBC, technologies for mutation detection, methods of interpreting genomic alterations, and an understanding of their clinical impact will aid practicing clinicians in the treatment of mBC as the field of breast oncology moves toward the era of precision medicine.

scholarly journals Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts

Breast Care ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. 275-281 ◽  
Author(s):  
Cornelia Liedtke ◽  
Hans-Christian Kolberg
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Systemic Therapy ◽  
Breast Cancer Subtype ◽  
Metastatic Breast ◽  
Parp Inhibitors ◽  
Current Evidence ◽  
Therapeutic Approaches ◽  
Pi3k Inhibitors

Systemic therapy of metastatic breast cancer may include chemotherapy, endocrine therapy, and targeted therapies (e.g., antibody-based approaches). These agents may be employed alone or in combination based on the patient's breast cancer subtype. Therefore, characterization of the disease phenotype is necessary and may include biopsy of the metastatic site. Novel therapeutic approaches include immunologic therapies, PARP inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, which are currently under investigation in clinical trials.

Novel therapeutic approaches to the treatment of metastatic breast cancer

2010 ◽  
Vol 36 (1) ◽  
pp. 33-42 ◽  
Author(s):  
Yolanda Fernández ◽  
Juan Cueva ◽  
Andrés G. Palomo ◽  
Manuel Ramos ◽  
Ana de Juan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Therapeutic Approaches ◽  
Novel Therapeutic
Sign in / Sign up

Export Citation Format

Share Document